Join
Live feed
·
PRReleasevia Quantisnow
Septerna Inc. logo

Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy

ByQuantisnow·Wall Street's wire, on your screen.
SEPN· Septerna Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SEPN (Septerna Inc.) and more on Quantisnow.